An amendment to this paper has been published and can be accessed via a link at the top of the paper.

doi.org/10.1038/s41375-020-0994-7, hdl.handle.net/1765/129300
Leukemia
Erasmus MC: University Medical Center Rotterdam

Ossenkoppele, G.J. (G. J.), Breems, D.A. (D. A.), Stuessi, G. (G.), van Norden, Y., Bargetzi, M., Biemond, B., A von dem Borne, P. (P.), Chalandon, Y. (Y.), Cloos, J., Deeren, D. (D.), Fehr, M. (M.), Gjertsen, B. (B.), Graux, C., Huls, G., Janssen, J.J.J.W. (J. J.J.W.), Jaspers, A. (A.), Jongen-Lavrencic, M., de Jongh, E. (E.), Klein, S.K. (S. K.), … Kuball, J. (2020). Correction: Lenalidomide added to standard intensive treatment for older patients with AML and high-risk MDS (Leukemia, (2020), 34, 7, (1751-1759), 10.1038/s41375-020-0725-0). Leukemia.https://doi.org/10.1038/s41375-020-0994-7